James Larkin
PhD, FRCP
Consultant Medical Oncologist
👥Biography 个人简介
James Larkin has been a leading investigator in both RCC and melanoma immunotherapy across European trials. He served as European principal investigator for the pivotal CheckMate-025 trial establishing nivolumab for second-line RCC and contributed to CheckMate-214. His cross-tumor expertise in checkpoint inhibitor toxicity management has informed multinational guidelines for irAE management.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 James Larkin 的研究动态
Follow James Larkin's research updates
留下邮箱，当我们发布与 James Larkin（Royal Marsden Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment